Pfizer Inc. (NYSE:PFE) Shares Sold by Flynn Zito Capital Management LLC

Flynn Zito Capital Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,471 shares of the biopharmaceutical company’s stock after selling 882 shares during the period. Flynn Zito Capital Management LLC’s holdings in Pfizer were worth $561,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its position in shares of Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after acquiring an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC bought a new stake in shares of Pfizer during the 4th quarter worth $255,000. Brookstone Capital Management boosted its holdings in Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares during the period. ETF Store Inc. boosted its holdings in Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares during the period. Finally, KLCM Advisors Inc. lifted its holdings in shares of Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on PFE shares. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Price Performance

PFE traded down $0.03 on Thursday, hitting $25.39. 35,459,235 shares of the stock were exchanged, compared to its average volume of 42,406,477. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.56. The business has a 50-day moving average of $27.19 and a two-hundred day moving average of $28.76. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market capitalization of $143.77 billion, a price-to-earnings ratio of 70.25, a PEG ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.